Last edition
News about "obesity "
Novo Nordisk Wins FDA Approval for Wegovy HD to Advance Obesity Treatment
FDA approves Novo Nordisk’s Wegovy HD (semaglutide 7.2 mg), a higher-dose weekly injection delivering significant weight loss, supported by strong Phase III trial outcomes.
Obesity | 21/03/2026 | By News Bureau | 120
India’s drug regulator Central Drugs Standard Control Organisation warns pharmaceutical firms against direct or indirect promotion of prescription-only GLP-1 drugs for obesity, stressing strict compliance with the Drugs and Cosmetics Act, 1940.
Obesity | 13/03/2026 | By News Bureau
Iqvia and DCRI have formed a strategic collaboration to enhance the design and execution of obesity and cardiometabolic clinical trials, combining global operational capabilities with academic research expertise.
Obesity | 12/02/2026 | By News Bureau | 176
Novo Nordisk Submits Updated Proposal to Acquire Metsera in Multi-Billion-Dollar Deal
Novo Nordisk has confirmed that it has submitted an updated, unsolicited proposal to acquire Metsera, which has been declared superior by Metsera’s board of directors.
Obesity | 06/11/2025 | By Dineshwori | 222
Eli Lilly And Cipla Partner to Distribute Yurpeak (Tirzepatide) in India
Eli Lilly and Cipla have signed an agreement to distribute and promote tirzepatide in India under a second brand name, Yurpeak.
Obesity | 27/10/2025 | By Dineshwori | 559
Pfizer to Acquire Metsera, Expand Obesity and Cardiometabolic Drug Pipeline
Pfizer is set to acquire Metsera, a clinical-stage biopharmaceutical company focused on developing the next generation of medicines for obesity and cardiometabolic diseases.
Obesity | 23/09/2025 | By Dineshwori | 180
Novo Nordisk presented new findings from its Wegovy and Cagrilintide trials in obesity management at the ongoing European Association for the Study of Diabetes (EASD) 2025 congress in Vienna, Austria.
Obesity | 17/09/2025 | By Dineshwori | 466
Novo Nordisk Reports 18% H1 Sales Growth, Lowers H2 Outlook for Wegovy and Ozempic
Novo Nordisk has announced its financial results for the first half of 2025, ending June 30, with sales rising 18 percent at constant exchange rates (CER) to DKK 154.9 billion (USD 24.78 billion).
Obesity | 06/08/2025 | By Dineshwori | 1703
Novo Nordisk Partners with Fangzhou to Transform Diabetes and Obesity Management
Novo Nordisk and Fangzhou have signed a Memorandum of Understanding (MoU) to collaborate on the management of serious chronic conditions, including diabetes and obesity. <br />
Obesity | 22/07/2025 | By Dineshwori | 407
Cipla to Enter Weight Management Segment, Expands Focus on Oncology and CNS Therapies
Cipla is set to enter India’s growing weight management market as part of its broader strategy to expand across emerging therapeutic segments.
Obesity | 14/07/2025 | By Dineshwori | 238
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy